<DOC>
	<DOCNO>NCT01481454</DOCNO>
	<brief_summary>The aim study assess safety profile quadrivalent influenza vaccine ( QIV ) demonstrate 3 different industrial lot QIV induce equivalent immune response children/adolescents ( 9 17 year age ) adult ( 18 60 year age ) . Primary Objective : - To describe safety profile ( injection site reaction systemic event ) vaccine 21 day follow vaccination , serious adverse event ( include adverse event special interest ) throughout study adult child/adolescent participant . Secondary Objectives : - To demonstrate 3 different industrial lot quadrivalent influenza vaccine ( QIV ) induce equivalent immune response 21 day post-vaccination age group ( lot consistency ) - To describe compliance immunogenicity QIV European Medicines Agency Note Guidance ( NfG ) ( CPMP/BWP/214/96 ) age group .</brief_summary>
	<brief_title>Study Quadrivalent Influenza Vaccine Administered Intramuscularly Children/Adolescents Adults</brief_title>
	<detailed_description>All participant receive single injection assign vaccine Visit 1 . They follow safety immunogenicity Day 21 post-vaccination ( Visit 2 ) , also monitor safety 6 month post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 9 11 year ( child ) , 12 17 year ( adolescent ) , 18 60 year ( adult ) day inclusion For child/adolescent subject , informed consent form sign dated parent ( ) ( subject , applicable local regulation ) , another legally acceptable representative ( independent witness , require local regulation ) , assent form sign date subject ( applicable local Ethics Committee country regulation ) . For adult subject , informed consent form sign date subject ( independent witness , require local regulation ) . Subject/subject parent/legally acceptable representative is/are able attend schedule visit comply trial procedure Covered health insurance , require local regulation . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) Participation time study enrollment plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 3 week follow trial vaccination Previous vaccination influenza 2012 Southern Hemisphere formulation 20112012 Northern Hemisphere formulation previous 6 month either trial vaccine another vaccine Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Selfreported thrombocytopenia , contraindicate intramuscular vaccination base investigator 's judgment Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination base investigator 's judgment Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction ( adolescent adult subject ) Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C ) . A prospective subject include study condition resolve febrile event subside Identified investigator employee investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural , adopt child ) investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Quadrivalent Inactivated Influenza Vaccine</keyword>
	<keyword>Trivalent Inactivated Influenza Vaccine</keyword>
</DOC>